Company intelligence / Profile preview

Deep Space Biology

Ownership: Private
Development stage: Preclinical

Overview

Deep Space Biology has developed "Yotta," an AI-powered platform that leverages microgravity data and machine learning to accelerate the discovery of biological relationships relevant to human health in space. The company claims its technology can reduce research timelines from years to seconds and has been recognized as a winner of the 2022 Care In Space Challenge. No clinical results or late-stage programs are publicly disclosed.

Therapeutic areas: Other
Modalities: AI-driven drug discovery (focus on identifying drug targets and therapeutics; specific modalities such as small molecules or biologics not explicitly stated)
Industry: Drug Discovery Services

Partnerships

Winner of the Care In Space Challenge (2022); other partnerships not specified

Beyond the preview

Go deeper on Deep Space Biology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deep Space Biology.

Explore the full profile